Beta hCG Levels in Bladder Cancer Patients
Author Information
Author(s): J. McLoughlin, T. Pepera, J. Bridger, G. Williams
Primary Institution: Department of Surgery, Hammersmith Hospital
Hypothesis
Can beta human chorionic gonadotrophin (BhCG) levels serve as a reliable tumor marker in bladder cancer?
Conclusion
The study found that elevated BhCG levels were only present in patients with poorly differentiated or metastatic bladder cancer.
Supporting Evidence
- Three patients with poorly differentiated transitional cell carcinoma had elevated BhCG levels.
- BhCG production was not demonstrated in well or moderately differentiated tumors.
- Previous studies indicated that BhCG levels could correlate with tumor differentiation.
Takeaway
Doctors checked the blood and urine of 62 patients with bladder cancer to see if a certain hormone, BhCG, could help tell how bad their cancer was. They found it only in some patients with more serious cancer.
Methodology
Serum and urine samples were collected from 62 patients, and BhCG levels were measured using a radio-immunoassay technique.
Limitations
The study had a small sample size and did not include a diverse range of tumor types.
Participant Demographics
41 male and 21 female patients, mostly postmenopausal women.
Want to read the original?
Access the complete publication on the publisher's website